Join to View Full Profile
3181 SW Sam Jackson Park RdPortland, OR 97239
Phone+1 503-494-6594
Fax+1 503-494-3257
Dr. Lopez is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 1995 - 1998
University of California (San Francisco)Residency, Internal Medicine, 1991 - 1994- University of California San Francisco School of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 1992 - Present
OR State Medical License 2001 - 2027
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Clinical Trials
- A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
- Targeted Pathway Inhibition in Patients With Pancreatic Cancer Start of enrollment: 2019 Aug 01
- NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer Start of enrollment: 2021 May 27
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- MYC serine 62 phosphorylation promotes its association with DNA double-strand breaks to facilitate repair and cell survival under genotoxic stress.Gabriel M Cohn, Colin J Daniel, Jennifer R Eng, Alannah S MacDonald, Jonathan St-Germain
Genes & Development. 2026-07-01 - Phase Ib Study to Assess the Safety of Neoadjuvant Trifluridine/Tipiracil With Concurrent Radiation in Resectable Stage II/III Rectal Cancer: The FIERCE Study.Emerson Y Chen, Nima Nabavizadeh, Nicholas D Kendsersky, Christopher Lessenich, Daniel O Herzig
Clinical Colorectal Cancer. 2026-06-01 - Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies.Jonathan J Hue, Mehrdad Zarei, Priyashree Sunita, Sami O Abul-Khoudoud, Goutam Dey
Cancer Research Communications. 2026-06-01
Journal Articles
- Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal AdenocarcinomaBrett Sheppard, Charles D Lopez, Zipei Feng, Clinical Cancer Research
Press Mentions
Peptomyc Announces Research IND Approval for Innovative Window of Opportunity Trial in Collaboration with OHSU Knight Cancer Institute, Portland, Oregon, USA, in PDAC PatientsSeptember 12th, 2024
Grant Support
- Mechanisms Linking ASPP2 To The RB/E2F And P53 PathwaysNational Cancer Institute2004–2008
- P53 And UV Regulation Of P53 Binding Protein Bbp/53bp2National Cancer Institute2001–2004
- P53 And UV Regulation Of P53 Binding Protein Bbp/53bp2National Cancer Institute2000–2001
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
